Rivaroxaban use in babies under 2 with blood clots
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at how a blood thinner called rivaroxaban is used in babies under 2 who have had a blood clot. It aims to understand safety and patterns of use to help guide treatment for young children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is under 2 years old.
- Your child has been diagnosed with a blood clot (venous thromboembolism) in the past 30 days.
- Your child has started a blood thinner (like rivaroxaban or another medication) recently.
- Your child has not been on any blood thinner in the past 6 months (or since birth if younger than 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood thinners (rivaroxaban pills versus LMWH shots) to see which is better at preventing blood clots in people with leg injuries that require a cast or brace. If you qualify, you can receive one of these treatments while your leg heals.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
This study looks at how a blood thinner called rivaroxaban enters breast milk after delivery. It may help women who need this medication while breastfeeding.
This trial studies whether rivaroxaban (a blood thinner) can help prevent dangerous clots in children age 2 and older who have “giant” coronary artery aneurysms after Kawasaki disease. Doctors will see if it’s safe and tolerable for children who are also on standard anti-clot/anti-platelet medications for the next 3 months.
This trial is testing the drug rivaroxaban in children aged 2 to 17 who have large bulges (aneurysms) in their heart arteries after Kawasaki disease. It aims to see how the drug works in the body to prevent blood clots.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.